HOUSTON, Nov. 18, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), today announced financial results for the three and six months ended June 30, 2025. Nutex Health is a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in 11 states and primary care-centric, risk-bearing physician networks.
Financial highlights for the three months ended June 30, 2025:
Financial highlights for the six months ended June 30, 2025:
Share Repurchase Program
On August 14, 2025, the Board of Directors authorized a stock repurchase program of up to $25.0 million of the Company's common stock over the next six months. We anticipate executing this program opportunistically pending compliance with the Company's current reporting obligations.
The purpose of the share repurchase program is to increase shareholder value and offset dilution from the issuance of additional shares related to stock compensation obligations for under-construction and ramping hospitals. Pursuant to the stock repurchase program, the Company may repurchase, from time to time, up to an aggregate of $25.0 million of the its outstanding shares of common stock, exclusive of any fees, commissions or other expenses related to such repurchases. The stock repurchase program permits the Company to repurchase shares of common stock at any time or from time to time at management's discretion in open market transactions made in accordance with the provisions of Rule 10b-18 and/or Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, privately negotiated transactions or by other means in accordance with applicable securities laws.
The timing of any repurchases and the number of shares repurchased are subject to the discretion of the Company and may be affected by various factors, including general market and economic conditions, the market price of the Company's common stock, the Company's earnings, financial condition, capital requirements and levels of indebtedness, legal requirements, and other factors that management may deem relevant. The share repurchase program authorization does not obligate the Company to acquire any shares of its common stock and may be amended, suspended or discontinued at any time.
Note: EBITDA and Adjusted EBITDA are non-GAAP financial metrics. A reconciliation of non-GAAP to GAAP measures is included below in this earnings release.
"We are pleased to report 217.5% revenue growth, Adjusted EBITDA attributable to Nutex Health of $144.4 million, a 643.5% increase in gross profit and a record high cash balance of $96.7 million, highlighting the company's continued financial strength and solid fundamentals as we execute on our growth plan for 2025," stated Jon Bates, Chief Financial Officer of Nutex Health.
"The arbitration process that we started in 2024 is now an ongoing part of our revenue cycle management process. In addition, the Company believes its shares are currently undervalued, and our share repurchase program underscores our confidence in the long-term prospects of Nutex Health. We anticipate executing this program opportunistically over the next several months with the goal of driving increased earnings per share and total shareholder return," stated Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health.
For more details on the Company's financial results for the three and six months ended June 30, 2025, please refer to our Quarterly Report on Form 10-Q filed with the U.S. Securities & Exchange Commission and accessible at www.sec.gov.
NUTEX HEALTH INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) | ||||
(In thousands, except share and per share amounts) | June 30, 2025 | December 31, | ||
Assets | ||||
Current assets: | ||||
Cash and cash equivalents | $ 96,733 | $ 40,640 | ||
Restricted short-term investments | — | 2,941 | ||
Accounts receivable | 349,220 | 232,449 | ||
Accounts receivable - related parties | 5,737 | 3,602 | ||
Inventories | 2,275 | 2,850 | ||
Prepaid expenses and other current assets | 19,060 | 9,997 | ||
Total current assets | 473,025 | 292,479 | ||
Property and equipment, net | 82,915 | 77,933 | ||
Operating lease right-of-use assets | 27,751 | 27,872 | ||
Financing lease right-of-use assets | 215,398 | 218,889 | ||
Intangible assets, net | 14,880 | 15,530 | ||
Goodwill, net | 13,919 | 13,919 | ||
Deferred tax assets | 12,852 | 7,987 | ||
Other assets | 288 | 711 | ||
Total assets | $ 841,028 | $ 655,320 | ||
Liabilities and Equity | ||||
Current liabilities: | ||||
Accounts payable | $ 28,076 | $ 9,614 | ||
Accounts payable - related parties | 1,975 | 806 | ||
Lines of credit | 7,859 | 3,554 | ||
Current portion of long-term debt | 18,951 | 14,395 | ||
Operating lease liabilities, current portion | 2,087 | 2,080 | ||
Financing lease liabilities, current portion | 7,072 | 7,705 | ||
Accrued arbitration expenses | 68,785 | 47,742 | ||
Accrued income tax expense | 8,364 | 26,533 | ||
Accrued stock-based compensation | 24,173 | 16,356 | ||
Accrued expenses and other current liabilities | 27,532 | 25,440 | ||
Total current liabilities | 194,874 | 154,225 | ||
Long-term debt, net | 20,463 | 22,466 | ||
Operating lease liabilities, net | 30,805 | 30,617 | ||
Financing lease liabilities, net | 258,009 | 259,479 | ||
Total liabilities | 504,151 | 466,787 | ||
Commitments and contingencies (Note 10) | ||||
Equity: | ||||
Common stock, $0.001 par value; 950,000,000 shares authorized; 6,595,109 and 5,511,452 shares | 7 | 6 | ||
Additional paid-in capital | 588,699 | 489,409 | ||
Accumulated deficit | (353,456) | (356,976) | ||
Nutex Health Inc. equity | 235,250 | 132,439 | ||
Noncontrolling interests | 101,627 | 56,094 | ||
Total equity | 336,877 | 188,533 | ||
Total liabilities and equity | $ 841,028 | $ 655,320 | ||
NUTEX HEALTH INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) | ||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||
(In thousands, except share and per share amounts) | 2025 | 2024 | 2025 | 2024 | ||||
Revenue: | ||||||||
Hospital division | $ 236,302 | $ 67,605 | $ 440,249 | $ 127,634 | ||||
Population health management division | 7,683 | 8,477 | 15,525 | 15,902 | ||||
Total revenue | 243,985 | 76,082 | 455,774 | 143,536 | ||||
Operating costs and expenses: | ||||||||
Payroll | 36,284 | 28,398 | 71,144 | 55,401 | ||||
Contract services | 61,109 | 9,505 | 99,764 | 20,825 | ||||
Medical supplies | 4,812 | 3,589 | 8,613 | 8,911 | ||||
Depreciation and amortization | 5,248 | 4,533 | 10,340 | 8,719 | ||||
Other | 11,608 | 7,496 | 22,651 | 16,962 | ||||
Total operating costs and expenses | 119,061 | 53,521 | 212,512 | 110,818 | ||||
Gross profit | 124,924 | 22,561 | 243,262 | 32,718 | ||||
Corporate and other costs: | ||||||||
Stock-based compensation | 78,747 | (61) | 106,389 | (12) | ||||
Impairment of assets | — | 3,474 | — | 3,474 | ||||
Impairment of goodwill | — | 3,197 | — | 3,197 | ||||
General and administrative expenses | 12,498 | 10,652 | 22,533 | 19,310 | ||||
Total corporate and other costs | 91,245 | 17,262 | 128,922 | 25,969 | ||||
Operating income | 33,679 | 5,299 | 114,340 | 6,749 | ||||
Interest expense, net | 5,678 | 5,054 | 11,798 | 9,499 | ||||
Gain on warrant liability | — | (3,060) | — | (5,661) | ||||
Other (income) expense | 4,269 | (599) | 7,594 | (840) | ||||
Income before taxes | 23,732 | 3,904 | 94,948 | 3,751 | ||||
Income tax expense | 7,588 | 894 | 27,998 | 1,283 | ||||
Net income | 16,144 | 3,010 | 66,950 | 2,468 | ||||
Less: net income attributable to noncontrolling interests | 33,841 | 3,374 | 63,430 | 3,196 | ||||
Net income (loss) attributable to Nutex Health Inc. | $ (17,697) | $ (364) | $ 3,520 | $ (728) | ||||
Income (loss) per common share | ||||||||
Basic | $ (2.95) | $ (0.07) | $ 0.60 | $ (0.15) | ||||
Diluted | $ (2.95) | $ (0.07) | $ 0.55 | $ (0.15) | ||||
NUTEX HEALTH INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) | ||||
Six Months Ended June 30, | ||||
(In thousands) | 2025 | 2024 | ||
Cash flows from operating activities: | ||||
Net income | $ 66,950 | $ 2,468 | ||
Adjustment to reconcile net income to net cash from operating activities: | ||||
Depreciation and amortization | 10,340 | 8,719 | ||
Gain on warrant liability | — | (5,661) | ||
Impairment of assets | — | 3,474 | ||
Impairment of goodwill | — | 3,197 | ||
Derecognition of goodwill | — | 453 | ||
Stock-based compensation expense | 106,389 | (12) | ||
Changes to deferred taxes | (4,865) | (2,341) | ||
Debt accretion expense | 504 | 579 | ||
Changes in operating assets and liabilities: | ||||
(Increase)/Decrease in Accounts receivable | (116,768) | (2,149) | ||
(Increase)/Decrease in Accounts receivable - related party | (2,135) | (425) | ||
(Increase)/Decrease in Inventories | 575 | 631 | ||
(Increase)/Decrease in Prepaid expenses and other current assets | (8,640) | (1,693) | ||
(Increase)/Decrease in Operating right-of-use assets | 121 | 162 | ||
Increase/(Decrease) in Accounts payable | 19,334 | (1,617) | ||
Increase/(Decrease) in Accounts payable - related party | 1,169 | 414 | ||
Increase/(Decrease) in Operating lease liabilities | 194 | (370) | ||
Increase/(Decrease) in Accrued arbitration expenses | 21,043 | — | ||
Increase/(Decrease) in Accrued income tax expense | (18,169) | — | ||
Increase/(Decrease) in Accrued expenses and other current liabilities | 2,180 | 10,482 | ||
Net cash provided by operating activities | 78,222 | 16,311 | ||
Cash flows from investing activities: | ||||
Acquisitions of property and equipment | (815) | (1,292) | ||
Proceeds from restricted short-term investment | 2,941 | — | ||
Cash related to sale of business | — | (711) | ||
Cash related to asset acquisition | (1,994) | — | ||
Net cash used in investing activities | 132 | (2,003) | ||
Cash flows from financing activities: | ||||
Proceeds from lines of credit | 4,606 | 132 | ||
Proceeds from notes payable | 258 | 4,915 | ||
Repayments of lines of credit | (301) | (594) | ||
Repayments of notes payable | (5,697) | (6,157) | ||
Repayments of finance leases | (2,593) | (1,440) | ||
Proceeds from common stock issuance, net issuance costs | — | 9,203 | ||
Members' contributions | 242 | 301 | ||
Members' distributions | (18,776) | (1,862) | ||
Net cash provided by (used in) financing activities | (22,261) | 4,498 | ||
Net increase in cash and cash equivalents | 56,093 | 18,806 | ||
Cash and cash equivalents - beginning of the period | 40,640 | 22,002 | ||
Cash and cash equivalents - end of the period | $ 96,733 | $ 40,808 | ||
Non-GAAP Financial Measures (Unaudited)
EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA are used as a supplemental non-GAAP financial measure by management and external users of our financial statements, such as industry analysts, investors, lenders and rating agencies. We believe EBITDA and Adjusted EBITDA are useful because it allows us to more effectively evaluate our operating performance.
We define EBITDA as net income (loss) attributable to Nutex Health Inc. plus interest expense, income taxes, depreciation and amortization.
We define Adjusted EBITDA as net income (loss) attributable to Nutex Health Inc. plus net interest expense, income taxes, depreciation and amortization, further adjusted for stock-based compensation, certain defined items of expense and any acquisition-related costs and impairments. Interest expense includes interest on lease liabilities, which is a component of total finance lease cost. A reconciliation of net income (loss) to Adjusted EBITDA is included below.
Beginning in the first quarter of 2025, we updated our presentation of Adjusted EBITDA to separately disclose finance lease payments related to leases under ASC 842. We believe this change provides greater transparency into our operating performance.
Adjusted EBITDA is not intended to serve as an alternative to U.S. GAAP measures of performance and may not be comparable to similarly-titled measures presented by other companies. Adjusted EBITDA follows (in thousands):
Three Months Ended June 30, | |||||||
2025 | 2024 | ||||||
Reconciliation of net loss attributable to Nutex Health Inc. to | (Updated) | (Prior) | (Updated) | (Prior) | |||
Net loss attributable to Nutex Health Inc. | $ (17,697) | $ (17,697) | $ (364) | $ (364) | |||
Depreciation and amortization | 5,248 | 5,248 | 4,533 | 4,533 | |||
Interest expense, net | 5,678 | 5,678 | 5,055 | 5,055 | |||
Income tax expense | 7,588 | 7,588 | 893 | 893 | |||
Allocation to noncontrolling interests | (1,275) | (1,275) | (1,628) | (1,628) | |||
EBITDA | (458) | (458) | 8,489 | 8,489 | |||
Gain on warrant liability | — | — | (3,060) | (3,060) | |||
Impairment of assets | — | — | 3,474 | 3,474 | |||
Impairments of goodwill | — | — | 3,197 | 3,197 | |||
Finance lease payments(1) | (6,675) | — | (5,191) | — | |||
Stock-based compensation | 78,747 | 78,747 | (61) | (61) | |||
Adjusted EBITDA | $ 71,614 | $ 78,289 | $ 6,848 | $ 12,039 | |||
Six Months Ended June 30, | |||||||
2025 | 2024 | ||||||
Reconciliation of net income (loss) attributable to Nutex | (Updated) | (Prior) | (Updated) | (Prior) | |||
Net income (loss) attributable to Nutex Health Inc. | $ 3,520 | $ 3,520 | $ (728) | $ (728) | |||
Depreciation and amortization | 10,340 | 10,340 | 8,719 | 8,719 | |||
Interest expense, net | 11,798 | 11,798 | 9,499 | 9,499 | |||
Income tax expense | 27,998 | 27,998 | 1,283 | 1,283 | |||
Allocation to noncontrolling interests | (2,572) | (2,572) | (3,172) | (3,172) | |||
EBITDA | 51,084 | 51,084 | 15,601 | 15,601 | |||
Gain on warrant liability | — | — | (5,661) | (5,661) | |||
Impairment of assets | — | — | 3,474 | 3,474 | |||
Impairment of goodwill | — | — | 3,197 | 3,197 | |||
Finance lease payments(1) | (13,038) | — | (10,163) | — | |||
Stock-based compensation | 106,389 | 106,389 | (12) | (12) | |||
Adjusted EBITDA | $ 144,435 | $ 157,473 | $ 6,436 | $ 16,599 | |||
(1) | Finance lease payments consist of cash payments for financing leases under ASC 842, which should be deducted from EBITDA. We believe this change is useful to investors to evaluate the ongoing operating performance of our business. |
About Nutex Health Inc.
Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division.
The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 24 facilities in 11 states.
The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups.
Forward-Looking Statements
Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will", "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Report on Form 10-Q for the three and six months ended June 30, 2025 under the heading "Risk Factors" in Part II, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.
| Last Trade: | US$99.20 |
| Daily Change: | -4.75 -4.57 |
| Daily Volume: | 103,300 |
| Market Cap: | US$551.550M |
September 22, 2025 March 20, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
